EraNova Confirms Classic Copper-Gold Porphyry System at Ruffner Target, Ruby Creek Project, BC Life Science Investing
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease Life Science Investing
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204 Life Science Investing
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease Life Science Investing
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights Life Science Investing
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency to Support Advancement to Pivotal Development Life Science Investing
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab for Relapsed/Refractory Multiple Myeloma Life Science Investing
Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026 Life Science Investing
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference Life Science Investing
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 Life Science Investing
